Qiagen Q1 2026 Earnings Call Transcript and Key Developments

Qiagen's Q1 2026 earnings call highlighted advancements in latent TB testing, including a new automated platform and AI tools. The company noted a growing market for IGRA tests and a new chemistry launch that improves lab efficiency. These developments could enhance Qiagen's market position in the $1.6 billion latent TB testing sector.

By Motley Fool Transcribing · Motley Fool · May 7, 2026, 15:02 UTC

Qiagen Q1 2026 Earnings Call Transcript and Key Developments

Tickers: $QGEN

Topics: AI automation DiaSorin IGRA Inpeco latent TB testing Qiagen QuantiFERON

Read the full article at Motley Fool

More World news

Major Corporate Earnings Scheduled for Release After Thursday Market Close Seeking Alpha · November 12, 2026, 15:00 UTC
U.S. Existing Home Sales Decline More Than Expected in October Seeking Alpha · November 12, 2026, 15:03 UTC
Ascendis Pharma Reports Strong Q3 2026 Results Driven by Yorvipath Growth Motley Fool · November 12, 2026, 15:09 UTC
Pomerantz Law Firm Investigates Omeros Corporation Following Regulatory Setbacks PR Newswire · November 12, 2026, 15:10 UTC
Pomerantz Law Firm Investigates Innodata Inc. Following Mass Layoffs and Stock Price Drop PR Newswire · November 12, 2026, 15:10 UTC
Nightview Fund Rebalances Portfolio with Exits from Autodesk and Las Vegas Sands Seeking Alpha · November 12, 2026, 15:05 UTC
Nvidia Traders Speculate on Successors Following Jensen Huang's Resignation CNBC · November 12, 2026, 15:06 UTC
Pomerantz Law Firm Investigates Cumberland Pharmaceuticals Following Clinical Trial Results and Stock Decline PR Newswire · November 12, 2026, 15:05 UTC
Bybit Launches Fiat-to-Crypto Rewards Campaign with 80,000 USDT Weekly Prize Pool PR Newswire · November 12, 2026, 15:06 UTC
U.S. Existing Home Sales Decline More Than Expected in October Seeking Alpha · November 12, 2026, 15:03 UTC